

Attorney Docket No.: 089889-000000US
Client Ref. No.:

PTO/SB/01A 10-05)

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76)**

Title of
Invention

USE OF DERIVATIVES OF SUCCINATE ESTERS FOR THE TREATMENT OF DEMENTIA

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, or
- ☒ Application No. 10/541,082, filed on June 29, 2005, the national
stage filing of International Application No. PCT/CN03/01155, filed December 31, 2003
- ☐ as amended on _____ (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

WARNING:

Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.

All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

FULL NAME OF INVENTOR(S)

Inventor one: Jianjun Zhang

Citizen of: People's Republic of China

Signature: Jianjun Zhang

Date: March 7, 2006

Inventor two: Jiangong Shi

Citizen of: People's Republic of China

Signature: Jiangong Shi

Date: March 7, 2006

☒ Additional inventors or a legal representative are being named on 1 additional form(s) attached hereto.

Attorney Docket No.: 089889-000000US
Client Ref. No.:

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN
APPLICATION DATA SHEET (37 CFR 1.76) -
ADDITIONAL INVENTOR(S)
Supplemental Sheet 1 of 1**

FULL NAME OF INVENTOR(S)

Inventor three: Yafang Wang Yafang Wang Citizen of: People's Republic of China

Signature: _____ Date: March 7, 2006

Inventor four: Dan Zhang Dan Zhang Citizen of: People's Republic of China

Signature: _____ Date: March 7, 2006

Inventor five: Mei Gao Mei Gao Citizen of: Peoples Republic of China

Signature: _____ Date: March 7, 2006

Inventor six: Yongchun Yang Yongchun Yang Citizen of: People's Republic of China

Signature: _____ Date: March 7, 2006

Inventor seven: Shengyang Huang Shengyang Huang Citizen of: People's Republic of China

Signature: _____ Date: March 7, 2006

Inventor eight: _____ Citizen of: _____

Signature: _____ Date: _____

Inventor nine: _____ Citizen of: _____

Signature: _____ Date: _____

Inventor ten: _____ Citizen of: _____

Signature: _____ Date: _____

Inventor eleven: _____ Citizen of: _____

Signature: _____ Date: _____

Inventor twelve: _____ Citizen of: _____

Signature: _____ Date: _____

60715318 v1

BEST AVAILABLE COPY

PTO/SB/01 (01-06)

**POWER OF ATTORNEY
and
CORRESPONDENCE ADDRESS
INDICATION FORM**

Application Number	10/541,082
Filing Date	June 29, 2005
First Named Inventor	Zhang, Jianjun
Title	USE OF DERIVATIVES OF SUCCINATE ESTERS FOR THE TREATMENT OF DEMENTIA
Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	089889-000000US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number:

20350

OR

☐ Practitioner(s) named below:

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number:

OR

☐ Firm or
Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.☒ Assignee of record of the entire interest. See 37 CFR 3.71.
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/06).

SIGNATURE of Applicant or Assignee of Record

Signature

Wang, Xibo-huang

Date

March 7, 2006

Name

Telephone

Title and Company

Title: legal representative

Company: Institute of Materia Medica, Chinese
Academy of Medical Sciences

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ *Total of _____ forms are submitted.

60715935 v1

BEST AVAILABLE COPY

PTO/SB/96 (12-05)

Attorney Docket No. 089869-000000US

STATEMENT UNDER 37 CFR 3.73(b)Applicant/Patent Owner: Jianjun Zhang et al.Application No./Patent No./Control No.: 10/541,082Filed/Issue Date: June 29, 2005Entitled: USE OF DERIVATIVES OF SUCCINATE ESTERS FOR THE TREATMENT OF DEMENTIAInstitute of Materia Medica, Chinese Academy of
Medical Sciences

(Name of Assignee)

a corporation

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
(The extent (by percentage) of its ownership interest is _____ %)

in the patent application/patent identified above by virtue of either:

- A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or a true copy of the original assignment is attached.

OR

- B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

- ☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Wang, Xiaoliang
Signature

march 7, 2006
Date

Printed or Typed Name

Legal Representative
Title

Telephone Number

COPY

Attorney Docket No.: 089889-000000US

ASSIGNMENT OF PATENT APPLICATION

WHEREAS, Jianjun Zhang of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; Jiangong Shi of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; Yafang Wang of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; Dan Zhang of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; Mei Gao of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; Yongchun Yang of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China; and Shengyang Huang of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China, hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified application for United States Letters Patent:

Title of Invention: USE OF DERIVATIVES OF SUCCINATE ESTERS FOR
THE TREATMENT OF DEMENTIA

Filing Date: June 29, 2005

Application No.: 10/541,082; and

WHEREAS, Institute of Materia Medica, Chinese Academy of Medical Sciences of No. 1, Xian Nong Tan Street, Xuanwu District, Beijing, 100050 People's Republic of China, hereinafter referred to as "ASSIGNEE," is desirous of acquiring ASSIGNORS' interest in the said invention and application and in any U.S. Letters Patent which may be granted on the same;

NOW, THEREFORE, TO ALL WHOM IT MAY CONCERN: Be it known that, for good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have sold, assigned and transferred, and by these presents do sell, assign and transfer unto the said Assignees, and Assignees' successors and assigns, all their right, title and interest in and to the said invention and application, and in and to any Letters Patent which may hereafter be granted on the same in the United States, the said interest to be held and enjoyed by said Assignees as fully and exclusively as it would have been held and enjoyed by said Assignors had this Assignment and transfer not been made, to the full end and term of any Letters Patent which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof.

Assignors further agree that they will, without charge to Assignee, but at Assignee's expense, cooperate with Assignee in the prosecution of said application and/or applications, execute, verify, acknowledge and deliver all such further papers, including applications for Letters Patent and for the reissue thereof, and instruments of assignment and transfer thereof, and will perform such other acts as Assignee lawfully may request, to obtain or maintain Letters Patent for said invention and improvement, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: March 7, 2006

Jianjun Zhang
Jianjun Zhang

Dated: March 7, 2006

Jiangong Shi
Jiangong Shi

BEST AVAILABLE COPY

COPY

Assignment

Attorney Docket No.: 089889-000000US

Page 2

Dated: March 7, 2006Yafang Wang

Yafang Wang

Dated: March 7, 2006Dan Zhang

Dan Zhang

Dated: March 7, 2006Mei Gao

Mei Gao

Dated: March 7, 2006Yongchun Yang

Yongchun Yang

Dated: March 7, 2006Shengyang Huang

Shengyang Huang

60716032 v1